SM
Sahajanand Medical Technologies Limited IPO
Medical Technology & Devices · Vascular & Structural Heart Intervention · Surat, Gujarat
📋 Mainline IPO
100% OFS
BSE, NSE
₹344
Upper Price
₹475.48 Cr
Issue Size
Oct 23, 2026
Listing Date
₹3,496.65 Cr
Market Cap
📅 IPO Timetable
All dates tentative🟢
IPO Opens
Thursday, 15 October 2026
Bidding starts — apply before close
🔒
IPO Closes
Monday, 19 October 2026
Last day to bid — closes at 5:00 PM IST
📊
Basis of Allotment
Wednesday, 21 October 2026
Allotment finalised by registrar
🔄
Refund & Share Credit
Thursday, 22 October 2026
Unallotted funds unblocked; shares credited to demat
🏷️
Friday, 23 October 2026
Trading begins on BSE & NSE from 10:00 AM IST
📋 IPO Details
IPO Open Date15 October 2026 (Thu)
IPO Close Date19 October 2026 (Mon)
Listing Date23 October 2026 (Fri)
Face Value₹1 per share
Price Band₹327 to ₹344
Issue Price (Upper Band)₹344 per share
Issue TypeBook Build — 100% OFS
Lot Size43 shares (Min App: 1 Lot / 43 Shares)
Total Issue Size1,38,22,116 shares (₹475.48 Cr)
Fresh Issue0 shares (₹0 Cr)
Offer for Sale (OFS)1,38,22,116 shares (₹475.48 Cr)
Pre-Issue Shares10,16,46,778
Post-Issue Shares10,16,46,778 (No equity dilution)
Promoter Holding (Pre → Post)40.82% → 36.20%
Market Cap (At Upper Band)₹3,496.65 Cr
Listing ExchangeBSE, NSE
Lead ManagersMotilal Oswal, Avendus, HSBC, Nuvama
RegistrarMUFG Intime India Pvt.Ltd.
💰 Lot Size & Minimum Investment
At upper price ₹344| Investor Type | Lots | Shares | Amount |
|---|---|---|---|
| Retail — Minimum | 1 | 43 | ₹14,792 |
| Retail — Maximum | 13 | 559 | ₹1,92,296 |
| S-HNI (sNII) — Min | 14 | 602 | ₹2,07,088 |
| S-HNI (sNII) — Max | 67 | 2,881 | ₹9,91,064 |
| B-HNI (bNII) — Min | 68 | 2,924 | ₹10,05,856 |
⚠️ Note: Investors can bid for a minimum of 43 shares and in multiples thereof.
👥 Investor Reservation
Allocated portion of Offer SizeMax 50%
QIB Portion
Min 35%
Retail Portion
Min 15%
NII Portion
📊 Subscription Status
Loading…
📈 Company Financials
Restated Consolidated · ₹ Crore| Metric | 30 Jun 2026 | 31 Mar 2026 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|---|
| Total Assets | 1,309.00 | 1,276.43 | 1,094.90 | 970.58 |
| Total Income | 354.33 | 1,218.73 | 1,035.96 | 908.59 |
| PAT | 15.09 | 69.08 | 25.15 | -7.35 |
| EBITDA | 48.58 | 170.66 | 128.02 | 110.05 |
| Net Worth | 631.72 | 616.05 | 545.23 | 526.30 |
| Reserves & Surplus | 706.86 | 692.48 | 580.71 | 556.57 |
| Total Borrowing | 320.63 | 269.53 | 224.96 | 175.27 |
Income Growth
FY 2023–24₹908.59 Cr
FY 2024–25₹1,035.96 Cr
FY 2025–26₹1,218.73 Cr
🎯 Key Performance Indicators
10.35%
ROE (Mar 26)
2.07% (Jun 26)
0.27
Debt/Equity (Mar 26)
0.33 (Jun 26)
11.57%
ROCE (Mar 26)
3.16% (Jun 26)
5.71%
PAT Margin (Mar 26)
4.29% (Jun 26)
14.10%
EBITDA Margin (Mar 26)
13.81% (Jun 26)
10.60%
RoNW (Mar 26)
2.31% (Jun 26)
5.48x
Price/Book
FY 2025–26
₹62.76
NAV (Mar 26)
₹64.35 (Jun 26)
⚖️ Valuation & EPS
Pre-IPO EPS
₹6.80
FY26 earnings + pre-issue shares
P/E: 50.59xPost-IPO EPS
₹5.94
FY26 earnings + post-issue shares
P/E: 57.91xPrice to Book Value
5.48x
At upper price band ₹344
Market Cap
₹3,496.65 Cr
At upper offer price ₹344
ℹ️
Because the issue is a 100% Offer for Sale (OFS), the total paid-up equity base remains unchanged at 10,16,46,778 equity shares post-issue. Valuation reflects an Upper Price Band Market Cap of ₹3,496.65 Cr based on FY26 PAT of ₹69.08 Cr and outstanding pre-issue equity shares.
🎯 Objects of the Issue
Proceeds distribution
The Sahajanand Medical Technologies Limited IPO is a 100% Offer for Sale (OFS) of 1,38,22,116 shares. The company will not receive any proceeds from the offer. The entire issue proceeds of ₹475.48 crore (after deducting offer expenses) will be transferred directly to the selling promoter and corporate shareholders.
Total OFS Proceeds Goal
₹475.48 Cr
🏢 About Sahajanand Medical Technologies Ltd.
Est. 2001 · Surat, Gujarat · Vascular & Structural Heart Intervention DevicesSahajanand Medical Technologies Limited, incorporated in October 2001, is a pioneering medical technology company dedicated to the development, manufacturing, and global distribution of technologically advanced medical devices focused primarily on vascular and structural heart interventions.
The company’s extensive product portfolio encompasses critical life-saving devices including coronary stents, coronary balloons, transcatheter aortic valve implantation (TAVI) devices, occluders, renal stents, and peripheral drug-coated balloons (DCBs). SMT focuses rigorously on research and development, high-precision manufacturing, and clinically backed product innovation, spearheading industry advancements with its flagship proprietary brands including Supraflex Cruz, Cocoon, and Hydra. The company operates a global supply chain backed by three integrated manufacturing facilities—two located in India and one in Thailand—complemented by dedicated R&D centres in both countries. As of June 30, 2026, SMT had 119 patents granted globally, with an additional 78 patent applications in the pipeline. By Fiscal 2026, its products were actively marketed across 77 countries utilizing direct, hybrid, and distributor-led models, establishing a deep market presence across India, Europe, and emerging global markets. As of June 30, 2026, the company supported 1,605 full-time employees, alongside 31 consultants and 707 contract personnel.
Brand Ecosystem
💓
Vascular & Heart Intervention
Advanced coronary stents, TAVI devices, balloons, and occluders under flagship brands Supraflex Cruz, Cocoon, and Hydra.
🏭
Global Manufacturing
Three state-of-the-art precision manufacturing facilities across India and Thailand serving global demand.
🔬
R&D & Patents
Two dedicated R&D centres holding 119 globally granted patents and 78 pipeline applications.
🌎
Global Marketing Network
Products marketed in 77 countries utilizing direct, hybrid, and distributor models primarily across India and Europe.
Competitive Strengths
🏆Technologically advanced medical devices engineered for high-barrier cardiovascular and structural heart segments.
🔬Robust R&D capabilities with a deep IP portfolio encompassing 119 granted global patents.
🌍Established leadership across India and key European markets, supported by an expansive sales network reaching 77 countries.
📈Strong financial scaling, reporting an 18% revenue increase to ₹1,218.73 Cr and a 175% surge in PAT to ₹69.08 Cr in FY26.
Company Promoters
BK
Bhargav Dhirajlal Kotadia & Dhirajlal Vallabhbhai Kotadia
Promoters, Sahajanand Medical Technologies Ltd.
PC
Priyanka Dhirajlal Cohen & Shree Hari Trust
Promoters, Sahajanand Medical Technologies Ltd.
Key Selling Shareholders (OFS)
Samara Capital Markets Holding Ltd.64,79,063 Shares (₹222.88 Cr)
Shree Hari Trust27,00,000 Shares (₹92.88 Cr)
Dhirajkumar Savjibhai Vasoya20,00,000 Shares (₹68.80 Cr)
NHPEA Sparkle Holding BV13,35,178 Shares (₹45.93 Cr)
Kotak Pre-IPO Opportunities Fund13,07,875 Shares (₹44.99 Cr)
📅 Key Dates
IPO Opens15 Oct 2026
IPO Closes19 Oct 2026
Allotment21 Oct 2026
Refund & Share Credit22 Oct 2026
Listing Day23 Oct 2026
💡 Quick Summary
Price Band₹327 – ₹344
Upper Price₹344 / share
Lot Size43 shares
Min. Investment (Retail)₹14,792 (1 Lot)
Issue Size₹475.48 Cr (OFS)
ListingBSE, NSE
🏦 Registrar & Lead Manager
Lead Managers
Motilal Oswal, Avendus Capital,
HSBC, Nuvama Wealth
HSBC, Nuvama Wealth
📍 Registered Address
Sahajanand Medical Technologies Ltd.
Sahajanand Estate, Wakharia Wadi,
NR. Dabholi Char Rasta Nani Ved, Ved Road,
Surat, Gujarat — 395004
📞 022 49564000
[email protected]
Sahajanand Estate, Wakharia Wadi,
NR. Dabholi Char Rasta Nani Ved, Ved Road,
Surat, Gujarat — 395004
📞 022 49564000
[email protected]
🛡️ Regulatory Note: Mainline IPO investments are subject to SEBI regulations. Always read the Prospectus/RHP before applying. Consult a SEBI-registered advisor before investing.
⚠️
Disclaimer: This page presents publicly available information from the Sahajanand Medical Technologies IPO RHP for informational purposes only. This format is generated adhering to the required structure as specified in the IPO NEW FORMAT source file. It does not constitute investment advice. IPO investments are subject to market risk. Please read all offer documents and consult a SEBI-registered advisor before investing.
📊
Track Sahajanand Medical Technologies IPO 2026: Price Band, GMP, Dates & Review GMP
Check real-time grey market premium, daily GMP history & estimated listing price.
Check GMP →